Why Are Most Peptides Injected Rather Than Taken Orally?

The absolute oral bioavailability of an unmodified peptide is often below 1% — the reason comes down to three sequential barriers the molecule has to survive.

First, the stomach's highly acidic environment denatures the peptide's three-dimensional folding — the shape that gives it biological activity — often before enzymatic digestion even begins. Second, digestive enzymes including pepsin, trypsin, chymotrypsin, and carboxypeptidases are specifically built to cleave peptide bonds, and they make no distinction between a piece of dietary protein and a therapeutic peptide. Third, whatever small fragments do survive digestion must then cross the intestinal epithelium, a barrier that's tightly selective for small molecules and individual amino acids rather than intact peptide chains.

Subcutaneous injection bypasses all three barriers, delivering the peptide directly into tissue where it's absorbed gradually and predictably — which is why it remains the standard route for essentially every peptide used in research today, despite active pharmaceutical research into oral peptide delivery technologies (enteric coatings, permeation enhancers, nanoparticle carriers) to eventually change that.